Chemical Component Summary

Identifiers 4,4'-(3E)-hex-3-ene-3,4-diyldiphenol
Formula C18 H20 O2
Molecular Weight 268.35 g/mol
Type non-polymer
Isomeric SMILES CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1
InChI InChI=1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+

Chemical Details

Formal Charge 0
Atom Count 40
Chiral Atom Count 0
Chiral Atoms
Bond Count 41
Aromatic Bond Count 12

Drug Info: DrugBank

DrugBank ID DB00255   (Stereoisomeric match)
Name Diethylstilbestrol
Groups approved
Description A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
  • (E)-3,4-bis(4-hydroxyphenyl)-3-hexene
  • (e)-4,4'-(1,2-Diethyl-1,2-ethenediyl)bisphenol
  • 4,4'-Dihydroxy-alpha,beta-diethylstilbene
  • 4,4'-dihydroxy-α,β-diethylstilbene
  • alpha,Alpha'-diethyl-(e)-4,4'-stilbenediol
  • Diethylstilbestrol diphosphate
  • Diethylstilbestrol diphosphate sodium
Brand Names
  • Honvol Ampoules 250mg
  • Honvol Tablets 100mg
  • Stilbestrol 0.5mg Tablet
  • Stilbestrol 1.0mg Tablet
  • Stilbestrol Tab 1mg
Affected Organism Humans and other mammals
Indication Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
Pharmacology Diethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
Mechanism of action Estrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Route of administration
  • Intravenous
  • Oral
  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • BCRP/ABCG2 Inhibitors
  • Benzene Derivatives
  • Benzylidene Compounds
  • L02AA01
  • G03CC05
  • L02AA04
  • G03CB02
AHFS-Code 68:16.04
CAS number 56-53-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682